Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869765 | 1.00 | FOLH1 (0.52) | FOLH1CTSLCTSSCTSBCTSK | |
| SCHEMBL12861495 | 0.86 | CTSS (0.53) | FOLH1CTSLCTSSCTSKANPEP | |
| SCHEMBL8249122 | 0.83 | FOLH1 (0.55) | FOLH1CTSLCTSSCTSKANPEP | |
| SCHEMBL8248672 | 0.83 | FOLH1 (0.55) | FOLH1CTSLCTSSCTSKANPEP | |
| SCHEMBL8255247 | 0.83 | FOLH1 (0.55) | FOLH1CTSLCTSSCTSKANPEP | |
| SCHEMBL5869744 | 0.83 | FOLH1 (0.55) | FOLH1CTSLCTSSCTSKANPEP | |
| SCHEMBL13624189 | 0.82 | CTSL (0.69) | CTSLCTSSCTSBCTSK | |
| SCHEMBL5670369 | 0.81 | CTSK (0.51) | FOLH1CTSLCTSSCTSBCTSK | |
| SCHEMBL7960075 | 0.79 | GPR88 (0.59) | FOLH1CTSLCTSSANPEP | |
| SCHEMBL8255411 | 0.79 | FOLH1 (0.51) | FOLH1CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | FOLH1 229/4885CTSL 911/4885CTSS 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.